News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Elsevier Science Appoints New Managing Director for Clinical Decision Support Group

2/13/2012 10:10:01 AM

PHILADELPHIA, Pennsylvania, February 13, 2012 /PRNewswire/ --

Jay Katzen leads the development of healthcare solutions that improve clinical decision-making, cost performance and patient outcomes

Elsevier, a world-leading provider of scientific, technical and medical information products and services, has appointed Jay Katzen as Managing Director of its Clinical Decision Support (CDS) group within Elsevier Health Sciences. Katzen will be responsible for all CDS operations and strategy, including product development, marketing, M&A and sales.

Jay brings more than 23 years of experience in delivering information and workflow solutions to researchers, clinicians, and executives to improve institutional outcomes. Most recently, he was the Managing Director of the Academic and Government Markets unit at Elsevier's Science & Technology division. In that role, Jay was responsible for product, marketing, strategy, M&A, and project and portfolio management. He led two acquisitions and delivered the SciVerse platform for scientific search and discovery, which includes SciVerse Hub and Application Marketplace and integrates ScienceDirect, Scopus, and Scirus. In addition, Jay led the strategy to define the new SciVal suite of solutions and services, enabling Elsevier to enter a new market for performance and planning at universities and government agencies.

Prior to joining Elsevier in 2007, he was the Senior Vice President of Marketing, Business Development and Knowledge Management at Micromedex, the Clinical Decision Support unit of Thomson Reuters. Prior to Thomson Reuters, he held the roles of Vice President of Marketing and Business Development with Unbound Medicine and Lexi-Comp, Inc.

"At the Academic & Government Markets unit, Jay drove innovation and integrated assets to accelerate discovery and extend value to researchers and research executives," said Michael Hansen, CEO, Elsevier Health Sciences. "I'm looking forward to having Jay bring that experience to create new solutions that allow healthcare professionals to provide better, safer and faster care and we are pleased to have Jay lead our efforts."

Elsevier's Clinical Decision Support solutions offer insight into the business of providing care, in areas from resource and performance management to drug information and clinical data analytics, as well as the tools healthcare organizations need to make better, more informed decisions around care delivery. These solutions enhance workflow and lead to better predictability and better outcomes via evidence-based medicine.

"I'm looking forward to leading the CDS business as we continue to build tools that allow healthcare professionals to evaluate, understand and implement strategies that improve outcomes and care quality," Katzen said. "We will focus on ensuring that Elsevier continues to deliver the highest quality solutions to the market."

Jay is based in Philadelphia and holds a B.A. in computer engineering from Case Western Reserve University and an M.B.A. from Cleveland State University.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier

SOURCE Elsevier

Read at

comments powered by Disqus